Oruka Therapeutics Reports Positive Phase 1 Data For ORKA-002

January 12, 2026 — 07:58 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Oruka Therapeutics, Inc. (ORKA) on Monday announced positive interim data from its Phase 1 trial of ORKA-002.

The study, conducted in healthy volunteers, evaluated the safety and pharmacokinetics of the drug. Interim results showed a half-life of 75-80 days, supporting the potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa. ORKA-002 was well tolerated at all dose levels, with no severe or serious treatment-emergent adverse events reported.

Phase 2 studies for ORKA-002 are expected to begin in the first half of 2026 in psoriasis and the second half of 2026 in hidradenitis suppurativa.

Meanwhile, a Phase 2b study of ORKA-001 dubbed EVERLAST-B is underway with data expected in 2027.

On Friday, Oruka shares closed at $27.86, up 5.53%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Oruka Therapeutics Reports Positive Phase 1 Data For ORKA-002

Tags

Latest Articles